EFI Lake Geneva Ventures

Annaida Technologies SA, founded in 2019 and based in Lausanne, Switzerland, specializes in the development of EmbryoSpin, an innovative device designed for biochemical research. This device performs microscopic nuclear magnetic resonance (µNMR) with a sensitivity that surpasses existing technologies by tenfold, allowing for chemical analysis at the scale of a single human embryo. EmbryoSpin is engineered for robustness and user-friendliness, making it suitable for non-invasive embryo viability screening in in-vitro fertilization and various biochemical studies. The company's advancements aim to enhance medical research capabilities, particularly in the context of reproductive health.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform aimed at treating various health conditions, particularly infections and blood-related diseases. Utilizing innovative magnetic blood purification technology, Hemotune's device employs magnetic beads to selectively and efficiently remove large biomolecules from the bloodstream. This approach focuses on addressing the immunological aspects of sepsis, enabling the targeted treatment of multiple disease pathways and improving patient outcomes in acute care settings.

Hylomorph AG is a MedTech company based in Zurich, Switzerland, focused on developing innovative solutions to address fibrotic encapsulation in implantable medical devices. Founded in 2014, the company specializes in a cellulose film designed to prevent the formation and adhesion of fibrotic tissue, thereby reducing the risk of implant failure. This technology is particularly applicable in cardiac and plastic surgery, where it aids surgeons during the implantation of devices such as pacemakers and neurostimulators. Hylomorph combines advanced biotechnology and surface micro-engineering to enhance the interaction between biological tissues and medical implants, ultimately aiming to improve patient outcomes and the overall quality of healthcare.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Seprify is a manufacturer specializing in cellulose-based products aimed at promoting sustainability within various industries. The company develops plant-based cellulose white pigments and opacifier solutions designed to serve as alternatives to traditional titanium dioxide. These pigments are derived from renewable materials that are cost-effective, biocompatible, and easily processed, allowing for scalability using established industrial methods. Seprify's offerings cater to a range of sectors, including paints, inks, cosmetics, pharmaceuticals, and food, enabling businesses to create safer and more sustainable products. By focusing on cellulose-based solutions, Seprify supports the transition toward a circular economy and encourages the adoption of environmentally friendly practices among its clients.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.